The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Results of a Trial Comparing Cabozantinib and Sunitinib in mRCC

Toni Choueiri, MD
Published Online:2:56 PM, Wed October 26, 2016

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the results of the ALLIANCE A031203 trial comparing cabozantinib and sunitinib in metastatic renal cell carcinoma (mRCC).
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.